Prescription Drug Supply Chain Pricing Transparency Act

Bill 118 HR 7535, also known as the Prescription Drug Supply Chain Pricing Transparency Act, aims to increase transparency in the pricing of prescription drugs within the supply chain. The bill requires drug manufacturers, wholesalers, and pharmacies to disclose information about the prices they charge for prescription drugs, including the cost of production, distribution, and any discounts or rebates offered.

The goal of the bill is to shed light on the often opaque pricing practices within the prescription drug supply chain, which can lead to higher costs for consumers. By requiring greater transparency, the bill seeks to empower consumers to make more informed decisions about their healthcare and potentially lower the cost of prescription drugs.

Additionally, the bill includes provisions to protect confidential information and trade secrets, ensuring that sensitive business information is not disclosed to competitors. It also establishes penalties for non-compliance with the transparency requirements, in order to incentivize compliance and ensure the effectiveness of the legislation. Overall, the Prescription Drug Supply Chain Pricing Transparency Act aims to promote fairness and accountability within the prescription drug supply chain, ultimately benefiting consumers by increasing transparency and potentially lowering the cost of prescription drugs.